Dupixent(dupilumab)
Dupixent (dupilumab) is an antibody pharmaceutical. Dupilumab was first approved as Dupixent on 2017-03-28. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat asthma, atopic dermatitis, esophageal diseases, prurigo, and sinusitis. The pharmaceutical is active against interleukin-4 receptor subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Dupixent (discontinued: Dupixent)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Dupilumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Dupixent | dupilumab | Regeneron Pharmaceuticals | N-761055 RX | 2017-03-28 | 4 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dupixent | Biologic Licensing Application | 2025-06-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atopic dermatitis | EFO_0000274 | D003876 | L20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
dupilumab, Dupixent, Regeneron Pharmaceuticals, Inc. | |||
| 2029-05-20 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
269 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis | D003872 | — | L30.9 | 9 | 16 | 22 | 28 | 33 | 106 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 9 | 15 | 20 | 27 | 33 | 103 |
| Eczema | D004485 | — | L30.9 | 6 | 14 | 16 | 22 | 20 | 78 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 7 | 10 | 13 | 18 | 49 |
| Rhinosinusitis | D000096825 | — | — | 1 | 1 | 7 | 9 | 15 | 33 |
| Nasal polyps | D009298 | — | J33 | — | 4 | 5 | 11 | 13 | 33 |
| Sinusitis | D012852 | EFO_0007486 | J32 | 1 | 3 | 3 | 4 | 5 | 16 |
| Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | 4 | 2 | 4 | 3 | 13 |
| Esophagitis | D004941 | HP_0100633 | K20 | — | 2 | 2 | 4 | 3 | 11 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | 4 | 2 | 1 | 2 | 10 |
Show 25 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urticaria | D014581 | EFO_0005531 | L50 | — | 2 | 4 | — | 1 | 7 |
| Neurodermatitis | D009450 | — | L28.0 | — | — | 5 | — | 2 | 7 |
| Prurigo | D011536 | — | L28.2 | — | — | 3 | — | 2 | 5 |
| Chronic urticaria | D000080223 | — | L50.8 | — | 1 | 3 | — | 1 | 5 |
| Skin diseases | D012871 | — | L00-L99 | 1 | — | 2 | — | 1 | 4 |
| Allergic fungal sinusitis | D000092562 | — | — | — | — | 3 | — | — | 3 |
| Bullous pemphigoid | D010391 | EFO_0007187 | L12 | — | 1 | 1 | — | 2 | 3 |
| Syndrome | D013577 | — | — | — | 2 | 1 | — | — | 2 |
| Immune system diseases | D007154 | — | D89.9 | — | — | 2 | — | — | 2 |
| Eczematous skin diseases | D017443 | — | — | — | — | 2 | — | — | 2 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Food hypersensitivity | D005512 | EFO_1001890 | — | 2 | 1 | — | — | 2 | 5 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | 2 | 3 |
| Nasopharyngeal neoplasms | D009303 | — | — | — | 1 | — | — | 2 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | 2 | 3 |
| Peanut hypersensitivity | D021183 | EFO_0007425 | — | — | 3 | — | — | — | 3 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | 3 | — | — | — | 3 |
| Alopecia | D000505 | — | L64 | — | 3 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 2 | — | — | 1 | 3 |
| Gastritis | D005756 | EFO_0000217 | K29.7 | — | 2 | — | — | — | 2 |
| Enteritis | D004751 | — | K52.9 | — | 2 | — | — | — | 2 |
Show 26 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | 1 | — | — | — | — | 1 |
| Apnea | D001049 | — | R06.81 | 1 | — | — | — | — | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | — | 3 | 3 |
| Conjunctivitis | D003231 | — | H10 | — | — | — | — | 3 | 3 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | — | — | 2 | 2 |
| Anosmia | D000086582 | — | — | — | — | — | — | 2 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
| Conjunctival diseases | D003229 | — | H10-H11 | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dupilumab |
| INN | dupilumab |
| Description | Dupilumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >6WG8:A|Dupilumab Fab heavy chain
EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLY
LQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGHHHHHH
>6WG8:B|Dupilumab Fab light chain
DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKI
SRVEAEDVGFYYCMQALQTPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTQGTTSVTKSFNRGEC |
Identifiers
| PDB | 6WG8, 6WGB, 6WGJ, 6WGK, 6WGL |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108675 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12159 |
| UNII ID | 420K487FSG (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
IL4R
IL4R
Organism
Homo sapiens
Gene name
IL4R
Gene synonyms
NCBI Gene ID
—
Protein name
Interleukin 4 receptor
Protein synonyms
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Dupixent – Sanofi
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Dupixent – Regeneron Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,840 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
306,536 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use